Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Hanawa, Shinsuke; Mitsuhashi, Akira; Usui, Hirokazu; Yamamoto, Nobuto; Nemoto, Miho Watanabe; Nishikimi, Kyoko; Uehara, Takashi; Tate, Shinichi; Umemura, Takashi; Shozu, Makio

doi:10.1097/igc.0000000000000436

Cited by 9 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a study by Hata et al [9] concluded that radiotherapy in cervical cancer patients older than 80 years of age is safe and effective, a number of elderly patients will only be offered palliative treatment, because comorbidity prevents them from tolerating the 5-6 weeks course of curative radiotherapy [10].…”

Section: Discussionmentioning

confidence: 99%

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

et al. 2016

View full text Add to dashboard Cite

Background The aim of this analysis was to describe trends in incidence, mortality, prevalence, and survival in Danish women with gynecologic cancer from 1980-2012 comparing women aged 70 years or more with younger women. Material and methods Gynecologic cancers included were ICD-10 codes C53 (cancer of the cervix uteri), C54 (corpus uteri cancer), C56 (ovarian cancer) and C57 (Fallopian tube cancer). Data derived from the NORDCAN database with comparable data on cancer incidence, mortality, prevalence and relative survival in the Nordic countries, where the Danish data are delivered from the Danish Cancer Registry and the Danish Cause of Death Registry with follow-up for death or emigration until the end of 2013. Results For cervical cancer the incidence decreased among women aged less than 70 years and remained stable among the elderly. The mortality rates were clearly separated by age groups with a 2-3 fold higher mortality rate among 70 + years-old than younger women. The mortality rates, however, decreased in all age groups from 1980-2012. For ovarian and Fallopian tube cancers the incidence was almost constant, whereas the average annual number of deaths decreased over time from 466 in 1980 to 396 in 2012. The mortality rates were clearly separated by age groups with mortality rates 3-4 times higher among the elderly. The mortality rate decreased among women less than 70 years during the entire period. The average annual number of newly diagnosed corpus uteri cancer increased from 631 in 1980 to 773 in 2012. The mortality rates were clearly separated by age groups with much higher mortality rates among the 70+ years-old as compared with younger women. Overall the mortality rates decreased from 1980 to 2012. Conclusion In gynecologic cancer both mortality rates and survival are age-dependent with a significantly shorter survival in the group of elderly.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In a Japanese study it was reported that all patients who received 40 mg/m 2 of weekly cisplatin developed grade 3 to 4 hematological toxicity, and only 36% of patients completed 5 cycles of administration (20). On the other hand, Hanawa et al (21) reported on daily low-dose cisplatin (8 mg/m 2 per day) and either low-or high-dose-rate IRBT. In our study the median total dose of cisplatin was 266 mg/m 2 , comparable to the recommended dose of cisplatin for Japanese women.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and Benefit of Concurrent Chemoradiotherapy for Elderly Patients with Uterine Cervical Cancer

Nosaka

Shibata

Utsumi

et al. 2016

Tumori

View full text Add to dashboard Cite

show abstract

“…In addition, a subanalysis found no difference in the incidence of adverse events and the 2‐year survival rate for patients around 75 years old with normal organ function. This means that, instead of changing treatment based solely on age, elderly patients should undergo evaluations of function and receive standard treatment if the relevant functions remain at adequate levels 25 …”

Section: Chemotherapy For Cervical Cancermentioning

confidence: 99%

Clinical management of chemotherapy for elderly gynecological cancer patients

Yoshida

Inoue

2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Since there are no established guidelines for the treatment of gynecological cancer in the elderly, medical treatment policy is currently decided by discussion with patients and their families based on doctors' experiences, referring to data from nonelderly patients and healthy elderly patients. The aim of this review was to clarify the current position of chemotherapy for elderly gynecological cancer patients and discuss the problems to be addressed in the future. Methods Little evidence has been accumulated for anticancer drug treatment in elderly individuals with gynecological cancer. This review presents outlines and representative papers on general cancer chemotherapy for the elderly, and problems that need to be solved in gynecological cancer fields in the future are identified. Results In 2018, the American Society of Clinical Oncology (ASCO) published guidelines for “Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary”. This guideline emphasizes that, when administering chemotherapy to patients over 65 years of age, vulnerabilities should be identified using geriatric assessment (GA). However, there have been no reports of clinical studies using GA in patients with cervical or uterine cancers, and only a few clinical studies using GA have been reported in patients with ovarian cancer. Conclusions Scoring systems suitable for elderly Japanese patients remain lacking. A Japanese gynecological GA needs to be developed in cooperation with other disciplines.

show abstract

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Abstract: Daily CCRT in patients 70 years and older had acceptable compliance and safety. Daily CCRT is suggested to be a good treatment option for elderly patients who have advanced cervical cancer and require concurrent cisplatin.

Cited by 9 publications

References 19 publications

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

Feasibility and Benefit of Concurrent Chemoradiotherapy for Elderly Patients with Uterine Cervical Cancer

Clinical management of chemotherapy for elderly gynecological cancer patients

Contact Info

Product

Resources

About